Alto Neuroscience, Inc.2024财年第三财季实现净利润-16.78百万美元

市场透视11-19

11月19日，Alto Neuroscience, Inc.（ANRO.US）公布财报，公告显示公司2024财年第三财季净利润为-16.78百万美元；其中营业收入为0.00美元，每股基本收益为-0.62美元。从资产负债表来看，Alto Neuroscience, Inc.（ANRO.US）总负债26.56百万美元，其中短期债务4.25百万美元，资产负债比为0.08，流动比率为0.14。机构评级：...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2484771913?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-19 18:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2484771913","market":"us","top_or_hot":-1,"title":"Alto Neuroscience, Inc.2024财年第三财季实现净利润-16.78百万美元","media":"市场透视","content":"<div>\n<p>11月19日，Alto Neuroscience, Inc.（ANRO.US）公布财报，公告显示公司2024财年第三财季净利润为-16.78百万美元；其中营业收入为0.00美元，每股基本收益为-0.62美元。从资产负债表来看，Alto Neuroscience, Inc.（ANRO.US）总负债26.56百万美元，其中短期债务4.25百万美元，资产负债比为0.08，流动比率为0.14。机构评级：...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180206a24562db&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alto Neuroscience, Inc.2024财年第三财季实现净利润-16.78百万美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlto Neuroscience, Inc.2024财年第三财季实现净利润-16.78百万美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-19 18:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180206a24562db&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月19日，Alto Neuroscience, Inc.（ANRO.US）公布财报，公告显示公司2024财年第三财季净利润为-16.78百万美元；其中营业收入为0.00美元，每股基本收益为-0.62美元。从资产负债表来看，Alto Neuroscience, Inc.（ANRO.US）总负债26.56百万美元，其中短期债务4.25百万美元，资产负债比为0.08，流动比率为0.14。机构评级：...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180206a24562db&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANRO","symbol_name":"Alto Neuroscience Inc","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180206a24562db&s=b","article_id":"2484771913","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180206a24562db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2484771913","pubTimestamp":1732010431,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月19日，Alto Neuroscience, Inc.公布财报，公告显示公司2024财年第三财季净利润为-16.78百万美元；其中营业收入为0.00美元，每股基本收益为-0.62美元。从资产负债表来看，Alto Neuroscience, Inc.总负债26.56百万美元，其中短期债务4.25百万美元，资产负债比为0.08，流动比率为0.14。机构评级：截至2024年11月19日，当前有6家机构对Alto Neuroscience, Inc.目标价做出预测，其中目标均价为12.75美元，其中最低目标价为4.00美元，最高目标价为29.98美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"ANRO":"Alto Neuroscience Inc"},"translate_title":"Alto Neuroscience, Inc. Achieved Net Income of-$16.78 Million in Fiscal Q3 FY24","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANRO":1},"content_text":"11月19日，Alto Neuroscience, Inc.（ANRO.US）公布财报，公告显示公司2024财年第三财季净利润为-16.78百万美元；其中营业收入为0.00美元，每股基本收益为-0.62美元。从资产负债表来看，Alto Neuroscience, Inc.（ANRO.US）总负债26.56百万美元，其中短期债务4.25百万美元，资产负债比为0.08，流动比率为0.14。机构评级：截至2024年11月19日，当前有6家机构对Alto Neuroscience, Inc.目标价做出预测，其中目标均价为12.75美元，其中最低目标价为4.00美元，最高目标价为29.98美元。公司简介：Alto Neuroscience Inc 是一家临床阶段的生物制药公司，其使命是通过利用个人的神经生物学来开发个性化和有效的治疗方案，重新定义精神病学。该公司目前包括不同的临床阶段资产，如ALTO-100、ALTO-202、ALTO-101和ALTO-300等，最初针对由独立的基于大脑的生物标志物识别的抑郁症和精神分裂症人群。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484771913"}